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Age-Related Differences in Breast Cancer Treatment 
David A. August, MD, Thomas Rea, MD, and Vernon K. Sondak, MD 
Background: More than half of the cases of breast cancer treated in the 
United States occur in women over age 65. This study investigates age-related 
differences in breast cancer therapy. 
Methods: A retrospective review of all women with primary operable inva- 
sive breast cancer treated at the University of Michigan Breast Care Center 
over a 30-month period showed a total of 77 older patients aged />65 years 
(median, 71; oldest patient, 92) for whom full information was available re- 
garding comorbidity, tumor stage and histology, and details of surgery, radia- 
tion, and chemohormonal therapy and complications. Fifty-one similar 
younger patients aged 55-64 years (median, 59) were identified for comparison. 
Patients were classified as either having received standard treatment or non- 
standard treatment. Standard therapy was prospectively defined as follows: 
local/regional--lumpectomy and axillary lymph node dissection plus radiation 
therapy or modified radical mastectomy; systemic--chemotherapy and/or ta- 
moxifen for stage II disease. A comorbidity score calculated for each patient 
assigned one point each for nursing home residence, nonambulatory status, 
recent surgery, and each medical problem requiring drug therapy. 
Results: When overall treatment (local/regional plus systemic) was assessed, 
proportionately fewer older patients (55 of 77 versus 47 of 51; p < 0.01) re- 
ceived standard treatment. Fewer older than younger patients (62 of 77 versus 
50 of 51; p < 0.01) received surgical therapy that included an axillary dissec- 
tion. A smaller proportion of older patients received radiation therapy follow- 
ing lumpectomy and axillary lymph node dissection (26 of 29 versus 19 of 19; 
N.S.). Overall, only 59 of 77 older patients versus 50 of 51 younger patients (p 
< 0.001) received standard local/regional care. Similar proportions of younger 
and older patients (19 of 22 and 24 of 30, respectively) received standard 
systemic therapy for stage II breast cancer, but older patients were less likely 
to receive chemotherapy than younger patients (7% versus 50%; p < 0.001). 
Treatment-related complications were not age-related but were more frequent 
in patients receiving standard treatment than in patients receiving nonstandard 
treatment (45 of 102 versus two of 26; p < 0.001). Comorbidity score correlated 
with the use of nonstandard therapy but not with age. The scores for both older 
and younger patients receiving overall standard treatment were 0.8 versus 1.5 
and 1.4, respectively, in patients receiving nonstandard treatment. Interest- 
ingly, explanations for decisions to deviate from standard treatment guidelines 
were often not identified. Comorbidity was explicitly noted in only one of four 
younger patients who received nonstandard treatment therapy. In 22 older 
patients who received nonstandard treatment, comorbidity was cited in eight 
cases, patient age was cited in six cases, and patient choice was cited in four 
cases. Follow-up (median, 34 months) did not show that disease-free or overall 
survival differences were related to age or to treatment (standard versus non- 
standard). 
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Conclusions: These data demonstrate age-related variations in breast cancer 
treatment in a multidisciplinary breast care unit. Lower complication rates and 
equivalent short-term outcomes in women who received nonstandard therapy 
suggest good clinical judgment may have played a role in these differences. 
Although age-related patient preferences and comorbidity are relevant, the 
age-related attitudes of caregivers must also be taken into account to fully 
explain these variations. 
Key Words: Breast cancer--Older women--Age--Treatment differences. 
Breast cancer is the second leading cause of can- 
cer mortality among women in the United States; 
for an American woman, the cumulative lifetime 
risk of being diagnosed with the disease approaches 
10% (1,2). Incidence rates for breast cancer begin to 
rise at age -30  years and continue to increase there- 
after. Thus, breast cancer becomes increasingly 
common with increasing age. It is estimated that 
half of the women who die from breast cancer are 
older than age 65 (2). Incidence and mortality data, 
however, do not reveal the full impact of breast 
cancer in older women. Because well over half of 
women aged 1>65 years survive their breast cancer 
(2), many older patients must live with the sequelae 
of their cancer and its treatment. Breast cancer is a 
life-threatening, stressful disease. The physical and 
psychosocial effects of the disease and its treatment 
begin with diagnosis, continue during therapy, and 
extend well beyond the completion of active inter- 
vention (3-5). As the population ages, the incidence 
and prevMence of breast cancer continue to rise, 
and women with breast cancer live longer, the cu- 
mulative impact of breast cancer and the sequelae 
of breast cancer treatment on the lives of the elderly 
is certain to grow. 
Using broad-based epidemiologic methods, in- 
vestigators have demonstrated that breast cancer 
treatment decisions are different for younger and 
older patients. Despite evidence attesting to their 
safety, the use of "aggressive" standard therapies 
such as mastectomy (6-9), lumpectomy with radia- 
tion therapy (I0,I 1), breast reconstruction (12), and 
adjuvant systemic therapy (13-16) is less frequent in 
the care of older women. Furthermore, increasing 
age correlates with decisions to deviate from "stan- 
dard" guidelines in the care of older women with 
breast cancer (12,17-25). 
Comorbidity does not fully explain the discor- 
dance between breast cancer care received by 
younger and older women (22). In addition to co- 
morbid disease, other factors must be examined to 
explain age-related differences in breast cancer 
therapy, including patient beliefs and values and 
provider beliefs and biases. Whatever the cause, it 
is not known whether these age-related deviations 
from "standard care" result in improved or poorer 
physical and psychosocial outcomes. 
To better understand how age influences the 
treatment of women with breast cancer, we must 
look beyond broad patterns of care to determine 
why individual patients receive various treatments 
and to determine the effect of those treatment 
choices on measures of outcome (treatment- and 
disease-related morbidity and mortality). The cur- 
rent study was undertaken to investigate age- 
related breast cancer therapy variations and the rea- 
sons for those variations on a case-by-case basis 
within a multidisciplinary unit specifically dedi- 
cated to breast care. This report emphasizes the 
interrelationships between patient age, therapy de- 
cisions, reasons for deviation from "standard ther- 
apy," and treatment-related morbidity. 
PATIENTS AND METHODS 
A retrospective review of all patients with pri- 
mary operable invasive breast cancer [American 
Joint Committee on Cancer (26) stages I and II] 
treated at the University of Michigan Breast Care 
Center (BCC) between January 1, 1988 and June 30, 
1990 was conducted to identify women aged >165 
years (older patients). A second group including all 
women aged 55-64 years (younger patients) treated 
during this same time period and meeting these cri- 
teria was also identified. This group of younger pa- 
tients was chosen for comparison with the older 
ones because they were also postmenopausal and 
approaching the age when comorbidity becomes 
more prevalent. Comorbidity, pathology, stage, 
treatment, and complication data were analyzed us- 
ing hospital records, tumor registry information, 
and a BCC computerized database. 
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The BCC is a multidisciplinary ambulatory care 
unit dedicated to the evaluation and treatment of 
benign and malignant breast disease (27). Virtually 
all of the evaluation and care of women with breast- 
related problems seen at the University of Michigan 
is provided by BCC clinicians. All breast cancer 
cases are discussed at a weekly multidisciplinary 
conference attended by surgical oncologists, radiol- 
ogists, medical oncologists, radiation oncologists, 
gynecologists, a plastic surgeon, a psychiatrist, 
nurse specialists, and social workers. Except in rare 
instances, treatment recommendations made to the 
patients described in this study represented a con- 
sensus opinion of this multidisciplinary team. 
For the purposes of this study, the generic ap- 
proach of BCC clinicians to the treatment of AJCC 
stage I and stage II invasive breast cancer (26) was 
used to define standard treatment. Standard ther- 
apy was prospectively defined as follows: local/ 
regional lumpectomy and axillary lymph node dis- 
section (ALND) plus radiation therapy or modified 
radical mastectomy (MRM) for stage I and stage II 
disease; systemicmchemotherapy and/or tamoxifen 
for stage II disease; overall both local/regional 
therapy (including both surgery and radiation) and 
systemic therapy standard. Any patient not receiv- 
ing standard therapy was classified as having re- 
ceived nonstandard treatment. 
To help analyze the influence of comorbid dis- 
ease on breast cancer treatment decisions, a comor- 
bidity scale was created. To calculate the comor- 
bidity score for an individual patient, one point each 
was assigned for nursing home residence, nonam- 
bulatory status, recent nonbreast surgery, and each 
medical problem requiring prescription drug ther- 
apy. The maximum score allowed was five. A co- 
morbidity score for each patient was calculated at 
the time therapy was initiated. 
Each patient's inpatient and outpatient record 
was reviewed to identify any explicitly stated rea- 
sons for deviations from standard therapy. To qual- 
ify as an explanation for deviation from standard 
therapy, a factor must have been explicitly identi- 
fied in a clinician's note as the reason for a partic- 
ular nonstandard treatment regimen to have been 
chosen. Factors qualifying as explanations for de- 
viations from standard therapy included comorbid- 
ity, patient choice, and patient age. In patients for 
whom none of these reasons was explicitly stated as 
the explanation for deviating from standard ther- 
apy, the reason was classified as "not  specified." 
All statistical comparisons were made using the 
X 2 test, with levels of significance ~<p = 0.05 being 
considered significant. 
RESULTS 
Patients and tumors 
Retrospective review of all patients with primary 
operable invasive breast cancer treated at the Uni- 
versity of Michigan BCC between January I, 1988 
and June 30, 1990 revealed 77 older women aged 
/>65 years at the time of initial breast cancer treat- 
ment (median, 71; oldest patient, 92) for whom 
information was available regarding comorbidity, 
tumor stage and histology, details of surgery, radi- 
ation, and chemohormonal therapy, and complica- 
tions of treatment. An additional 51 younger women 
aged 55-64 years (median, 59) meeting these criteria 
were identified for comparison. There were no dif- 
ferences between the two groups in pathologic tu- 
mor stage (clinical staging of axillary nodes was 
used for patients who did not undergo ALND), his- 
tology, or estrogen receptor status (Table 1). 
Local regional treatment 
With standard surgical therapy defined as appro- 
priate local surgery (lumpectomy or mastectomy) 
TABLE 1. T u m o r  c h a r a c t e r i s t i c s  
No. of No. of 
Tumor older patients younger patients 
characteristics (>/65) (55-64) 
Stage 
T1NoM o 38 (49%) 28 (55%) 
T1N×M o 9 (12%) 1 (2%) 
ToN1M0 - -  1 (2%) 
T~NIM 0 5 (6%) 8 (16%) 
TxN1M o 1 (1%) - -  
T2NoMo 14 (18%) 5 (10%) 
T2N1M o 6 (8%) 7 (14%) 
T2NxMo 4 (5%) 1 (2%) 
Stage I 47 (61%) 29 (57%) 
Stage II 30 (38%) 22 (43%) 
Histology 
Invasive ductal 66 (86%) 45 (88%) 
Invasive lobular 6 (8%) 2 (4%) 
Invasive ductal 
and lobular 4 (5%) 2 (4%) 
Papillary 1 (1%) 1 (2%) 
Tubular - -  1 (2%) 
Estrogen receptors 
Positive 44 (57%) 35 (69%) 
Negative 10 (13%) 9 (18%) 
Undetermined ~ 23 (30%) 7 (14%) 
Lymph node status was determined pathologically. Those pa- 
tients in whom pathologic lymph node information was not avail- 
able were staged clinically. 
Original biopsy performed elsewhere and no tissue available 
for estrogen receptor determination. 
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combined with ALND, older patients were less 
likely to receive standard surgical therapy than 
younger patients (81% versus 98%, p < 0.01) (Ta- 
ble 2). 
Of the 42 older patients who underwent lumpec- 
tomy, 81% received radiation therapy; all 20 
younger patients who received breast-conserving 
therapy also received radiation therapy. This differ- 
ence is statistically significant (p < 0.05) (Table 3). 
Interestingly, older patients were more likely than 
younger patients to receive breast-conserving ther- 
apy (54% versus 39%, p < 0.05). Standard breast- 
conserving breast cancer treatment was defined as 
lumpectomy with ALND plus radiation therapy. 
The greater frequency of breast conservation in 
older women was attributable primarily to the 
greater proportion of older women who received 
nonstandard breast-conserving surgery in the form 
of lumpectomy without ALND. 
Combining surgery and radiation therapy data 
(Table 3), we found that only 77% of older patients 
versus 98% of younger patients (p < 0.001) received 
standard local/regional treatment (lumpectomy and 
ALND plus radiation therapy or MRM). 
Systemic treatment 
Similar proportions of older patients and younger 
patients received standard systemic therapy (adju- 
vant chemotherapy and/or tamoxifen) following 
surgery for stage II breast cancer (24 of 30 older 
patients versus 19 of 22 younger patients). Older 
patients, however, were far less likely than younger 
patients to receive chemotherapy (7% versus 50%, 
p < 0.001). 
TABLE 2. Surgery according to age 
Surgery 
No. of older No. of younger 
patients patients 
(/>65) (55-64) 
Lumpectomy alone 13 (17%) 1 (2%) 
Lumpectomy/ALND 29 (38%) 19 (37%) 
MRM 33 (43%) 31 (61%) 
TM 2 (3%) 
Standard therapy 62 (81%)" 50 (98%) a 
Nonstandard therapy 15 (19%)" 1 (2%) a 
Standard surgical therapy was defined as appropriate local sur- 
gery (lumpectomy or mastectomy) combined with axillary node 
dissection, All other surgical treatment was defined as nonstan- 
dard, 
ALND, axillary lymph node dissection; MRM, modified rad- 
ical mastectomy; TM, total mastectomy (without axiUary lymph 
node dissection). 
a Significant difference between older and younger patients, 
p < 0.01. 
TABLE 3. Local~regional treatment  according to age 
Treatment 
No. of 




plus RT, or MRM 59 (77%) 50 (98%) 
Lumpectomy alone 11 (14%) - -  
Lumpectomy/ALND alone 3 (4%) - -  
Lumpectomy plus RT only 2 (3%) 1 (2%) 
Total mastectomy alone 2 (3%) - -  
Standard therapy 59 (77%)" 50 (98%) ~ 
Nonstandard therapy 18 (23%) a 1 (2%) ~ 
Standard local/regional therapy was defined as lumpectomy 
and axiUary lymph node dissection plus radiation therapy or 
modified radical mastectomy. 
ALND, axillary lymph node dissection; RT, radiation therapy; 
MRM, modified radical mastectomy. 
a Significant difference between older and younger patients, 
p < 0.001. 
Overall treatment 
Assessing overall treatment (local/regional plus 
systemic), we found that a significantly smaller pro- 
portion of older than younger patients received 
standard treatment (71% versus 92%, p < 0.01). 
This difference was primarily attributable to the fact 
that a greater proportion of older women did not 
receive standard local/regional therapy (Table 4). 
Comorbidity 
Comorbidity scores did not correlate with age. 
The mean comorbidity score in older patients was 1.0; 
in younger patients, it was 0.8. There was a correla- 
tion between comorbidity scores and the use of 
standard versus nonstandard therapy. For patients 
receiving standard therapy, the mean comorbidity 
score was 0.8 overall and 0.8 for both older and 
younger patients. For patients receiving nonstand- 
ard therapy, the mean comorbidity score was 1.4 
(1.4 for older patients and 1.5 for younger patients). 
Complications 
Complications of therapy occurred with equal 
frequency in both age groups (Table 5). Complica- 
tions occurred in 26% of older patients and 35% of 
younger patients. The majority of these complica- 
tions were minor wound infections, postoperative 
seromas, or radiation therapy-induced superficial 
skin desquamation. Serious complications were 
rare in both older and younger patients. The serious 
complications observed included two episodes of 
deep venous thrombosis and one episode of neutro- 
penia in older patients, and one episode of deep 
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TABLE 4. Overall treatment according to age 
% of 
% of younger 
Local/ older patients patients 
regional Systemic Overall (n = 77) (n = 51) 
Standard Standard Standard 71 ~ 926 
Standard Nonstandard Nonstandard 5 6 
Nonstandard Standard Nonstandard 21 a 2 a 
Nonstandard Nonstandard Nonstandard 3 0 
Overall treatment was defined as standard if both local/regional treatment was stan- 
dard (lumpectomy and axillary lymph node dissection plus radiation therapy or modified 
radical mastectomy) and systemic treatment was standard (tamoxifen or chemotherapy 
for stage II disease). 
a Significant difference between older and younger patients, p < 0.01. 
venous thrombosis and six episodes of neutropenia 
in younger patients. There were no treatment- 
related deaths. When analyzed by type of therapy 
received, therapy-related complications were more 
frequent in patients receiving standard treatment 
versus nonstandard treatment (44% versus 8%, p < 
0.001). 
Reasons for nonstandard treatment 
A case-by-case analysis of reasons for patients 
not receiving standard therapy was performed and 
is summarized in Table 6. One younger patient re- 
ceived nonstandard local/regional treatment be- 
cause of comorbidity. She had severe obstructive 
pulmonary disease and could not safely undergo 
general anesthesia for ALND. Three younger pa- 
tients did not receive standard systemic therapy for 
stage n disease; one refused treatment because of 
an insurance problem (patient choice), and the rea- 
son for nonstandard therapy was not specified for 
the other two patients. 
Of the 22 older patients who received nonstan- 





Older patients (/>65) 
Younger patients (55--64) 
Overall standard treatment ~ 
Overall nonstandard treatment 
20/77 (26%) 
18/51 (35%) 
45/102 (44%) b 
2/26 (8%) b 
a Overall treatment was defined as standard if both local/ 
regional treatment was standard (lumpectomy and axillary lymph 
node dissection plus radiation therapy or modified radical mas- 
tectomy) and systemic treatment was standard (tamoxifen or 
chemotherapy for stage II disease). 
b Significant difference between patients receiving overall 
standard treatment and patients receiving overall nonstandard 
treatment, p < 0.00t. 
dard therapy, age was the reason specified for six. 
These six patients had a median age of 85 (versus 76 
for those older women receiving nonstandard treat- 
ment in whom age was not given as the reason). 
Although it was not specifically stated, it appears 
that reluctance to subject these women to general 
anesthesia played a rote in their receipt of nonstan- 
dard treatment, since none of them underwent 
ALND or a procedure requiring general anesthesia. 
For eight older patients, comorbidity was cited as 
the reason for nonstandard care. Five of these pa- 
tients did not receive radiation therapy following 
lumpectomy because of impaired mobility. Two 
others underwent lumpectomy and radiation ther- 
apy and received tamoxifen; cardiovascular disease 
was identified as the reason for not undertaking 
ALND. The eighth patient received neither radia- 
tion therapy nor systemic therapy following lump- 
ectomy and ALND (one of six nodes positive) be- 
cause of her inability to reliably return for follow- 
up. Of the remaining eight older patients who 
received nonstandard therapy, four refused recom- 
mended standard treatment and in four the reason 
was not specified. 
Short-term follow-up (median, 34 months) did not 
reveal any differences in either disease-free or over- 
all survival between older patients and younger pa- 
tients or between those patients receiving standard 
or nonstandard treatment (Table 7). 
TABLE 6. Reasons for  nonstandard therapy 
Reason 
No. of No. of 
older patients younger patients 
(>165) (55-64) 
Age 6 
Comorbidity 8 1 
Patient choice 4 t 
Not specified 4 2 
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TABLE 7. Curren t  breas t  cancer  s ta tus  
No. of No. of 
Current older patients younger patients 





Alive, no cancer 59 (77%) 42 (80%) 8t (79%) 20 (77%) 
Dead, no cancer 7 (9%) 2 (4%) 5 (5%) 4 (15%) 
Alive, cancer 6 (8%) 4 (8%) 9 (9%) 1 (4%) 
Dead, cancer 5 (6%) 3 (6%) 7 (7%) 1 (4%) 
DISCUSSION 
Because half of all breast cancer deaths in the 
United States occur in women over the age of 65 
years (1,2), breast cancer may be thought of as pri- 
marily a disease of older women. Unfortunately, 
older women generally have been underrepresented 
in many of the prospective, randomized trials that 
established the principles of breast cancer treat- 
ment (2,28). Epidemiologic data, however, demon- 
strate that older women with breast cancer receive 
different diagnostic and therapeutic interventions 
than do similarly afflicted younger women (18-25). 
In light of these facts, we set out to answer the 
following three questions: First, in a specialized, 
multidisciplinary unit dedicated to the treatment of 
breast disease, do older women (age ~>65 years) re- 
ceive different treatment from younger women? 
Second, if there are age-related treatment differ- 
ences, what are the factors that contribute to these 
variations? Finally, what are the effects of age- 
related treatment variations on disease- and treat- 
ment-related morbidity and mortality? 
The data presented demonstrate that even in a 
specialized, multidisciplinary unit dedicated to the 
treatment of breast disease, there are clear differ- 
ences in the treatment older and younger women 
receive for primary operable (stage I and II) inva- 
sive breast cancer. Older patients were less likely to 
receive standard surgical therapy, less likely to re- 
ceive radiation therapy following lumpectomy, and 
less likely to receive standard local/regional treat- 
ment (lumpectomy, ALND, plus radiation therapy 
or modified radical mastectomy). Although older 
and younger women were equally likely to receive 
adjuvant systemic therapy in the presence of stage 
II disease, the older women were more likely to 
receive tamoxifen only (rather than chemotherapy). 
These differences in various components of breast 
cancer therapy meant that overall, whereas 92% of 
women under the age of 65 years received standard 
treatment, only 71% of older women received stan- 
dard treatment. These differences were observed 
even though the two groups in this study were se- 
lected to avoid variables confounding age-related 
factors. Tumor stage, pathology, and receptor sta- 
tus were comparable. The younger women (aged 
55-64) were all postmenopausal. Furthermore, gen- 
eral comorbidity was comparable between younger 
and older patients. 
The age-related differences in treatment must be 
considered in the light of the following two facts: (a) 
Few older women have been included in definitive 
breast cancer treatment trials (2,28); and (b) studies 
suggest that age does not influence either the effi- 
cacy or toxicity of surgery, radiation therapy, or 
chemohormonal therapy for breast cancer treat- 
ment (6-16). Thus, there is little evidence to suggest 
that older women should be treated differently from 
younger women. Nevertheless, age-related treat- 
ment differences are not limited to the present 
study; they have also been reported by other inves- 
tigators. 
To better understand the basis for these age- 
related differences in breast cancer treatment, we 
looked at some general and individual factors that 
might have influenced breast cancer treatment 
choices. Comorbidity did not play a major role in 
choices to deviate from standard therapy. Gener- 
ally, comorbidity scores were comparable between 
women in the two groups. The presence of comor- 
bid diseases was cited as the reason to use non- 
standard treatment in approximately one-quarter of 
the younger patients and one-third of the older pa- 
tients who did not receive standard therapy. Simi- 
larly, although patient choices occasionally resulted 
in the use of nonstandard therapy, older women 
were no more likely than younger women to decline 
standard treatment. The striking difference in rea- 
sons to forgo standard treatment in individual cases 
was the identification of age as the primary indica- 
tion for nonstandard treatment in 27% of older 
women not receiving standard treatment. Thus, 
chronologic (as opposed to physiologic) age was a 
significant factor that influenced physician recom- 
mendations to patients concerning optimal breast 
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cancer treatment. In the absence of clinical data to 
support the use of chronologic age as a predictor of 
response to therapy or of the likelihood of compli- 
cations, it is equally plausible to attribute this age 
effect to physician bias ("ageism") or exercise of 
good clinical judgment. 
To analyze the possible role of physician bias and 
clinical judgment on decisions to treat older and 
younger patients differently, we assessed the rela- 
tionship of treatment-associated complications and 
disease outcomes to treatment choices. In both 
older and younger patients, the mean comorbidity 
score was higher in women who received nonstan- 
dard treatment than in those who received standard 
treatment; this suggests that clinical judgment 
played at least some role in choices to deviate from 
standard care. 
Complication rates were comparable between 
older and younger women, but they were clearly 
higher in women who received standard care; again, 
clinical judgment appears to play a role in avoiding 
some complications. Of the I0 serious complica- 
tions observed, nine were attributable to systemic 
chemotherapy. This finding may have influenced 
some decisions to avoid chemotherapy in older 
women. The more frequent use of nonstandard care 
in older patients also correlated with the more fre- 
quent use of breast-conserving therapy. Disease 
outcomes (i.e., recurrence and survival) with a me- 
dian follow-up of 34 months were similar for both 
groups, indicating that at least in the short term, 
choices in favor of nonstandard care did not ad- 
versely affect treatment results. Thus, there is am- 
ple evidence to suggest that good clinical judgment 
played a substantial role in age-related differences 
in breast cancer treatment decisions. Nevertheless, 
a case-by-case analysis clearly demonstrated that 
age in and of itself also biased treatment recommen- 
dations. 
In toto, these data may be interpreted in at least 
two alternative fashions. Given that age in and of 
itself was not predictive of treatment- or disease- 
related morbidity or mortality, one could argue that 
chronologic age not be allowed to influence breast 
cancer treatment recommendations to patients. 
Standard therapy should be offered to all patients, 
regardless of age, in the absence of specific con- 
traindications (comorbidity or strong, informed pa- 
tient preference). Alternatively, given a greater fre- 
quency of  breast -conserving therapy in older 
women and equivalent disease outcomes and fewer 
complications in women receiving nonstandard 
therapy (and presumably less treatment-related dis- 
comfort and inconvenience in this less aggressively 
treated group of women), clinicians should be en- 
couraged to exercise their clinical judgment more 
frequently to recommend nonstandard treatment to 
both older and younger women. 
It may in fact be the case that women of all ages 
should be receiving less therapy than is currently 
standard. Treatment of breast cancer has evolved 
dramatically over the past 2 decades and will un- 
doubtedly continue to change over the next 10 
years. These changes may direct us to more "non- 
s tandard,"  less aggressive treatment for most 
women with breast cancer. An informed choice be- 
tween more standard or more nonstandard treat- 
ment must await clinical trials to determine the rel- 
ative merits of broadly applied standard treatment 
protocols versus individualized treatment planning 
not only based on trial-proven therapeutic ap- 
proaches but also allowing for clinical judgment and 
physician bias. 
Whether or not breast cancer treatment recom- 
mendations should differ according to patient age, it 
is clear that older women assess treatment options 
presented to them differently. Using open-ended in- 
terviews, Peters (29) explored the breast cancer be- 
liefs of a group of older breast cancer patients 
(mean age, 60 years; range, 4%80). Patients viewed 
themselves as passive victims of causative agents. 
Although nearly all expressed confidence in their 
physicians, 89% believed that their prognosis was 
dependent upon God. Over 90% identified the in- 
ability to care for themselves and perform everyday 
tasks as the worst aspects of their illness. Passivity 
in older women with breast cancer has also been 
observed by other investigators (30,31). These find- 
ings suggest that two important factors are relevant 
to breast cancer treatment in older women. First, 
the confidence (blind faith?) of older patients in 
their physicians indicates that patients will listen to, 
evaluate, and often accept their doctors' recom- 
mendations regarding the safety and benefits of 
therapeutic alternatives. Second, the concern of 
older patients over their ability to care for them- 
selves and perform habitual tasks highlights their 
potential reluctance to undergo standard therapy 
unless their physicians take the time to thoroughly 
discuss options and consequences with them. 
In summary, these data demonstrate clear age- 
related variations in breast cancer treatment within 
a dedicated, multidisciplinary breast care unit. 
Lower complication rates and equivalent short- 
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term outcomes in women receiving nonstandard 
therapy suggest that good clinical judgment plays a 
role in these differences. Although case-by-case 
analysis also indicates that age-related patient pref- 
erences and comorbidity are relevant, chronologic 
age is also a factor that must be considered to fully 
account for these variations. 
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